BioSpace News Archive

IDEAYA Biosciences, Inc., a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in upcoming investor relations events.

Vivani Medical, Inc. announced that its wholly-owned subsidiary Cortigent, Inc., a company pioneering targeted neurostimulation technology to recover critical body functions, will present the Early Feasibility Study results for the Orion® Visual Cortical Prosthesis System at The Eye & The Chip: 13th World Research Congress on Artificial Vision in Southfield, Michigan on October 8-10, 2023.

Henry Schein, Inc. announced that the Company will present at the following investor conferences: Morgan Stanley 21st Annual Global Healthcare Conference in New York on September 11, 2023, at 10:00 a.m. Eastern time.

Crossject (ISIN: FR0011716265; Euronext:ALCJ) announces that its manufacturing sites in Dijon and Gray (France) have passed an annual ISO certification audit, expanded their scope of certification by French Health Agency, and received positive feedback after an audit by the Biomedical Advanced Research and Development Authority (BARDA).

Galera Therapeutics, Inc. announced that Mel Sorensen, M.D., President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 25th Annual Global Investment Conference on Monday, September 11, 2023, at 4:30 p.m. E.T.

Cara Therapeutics, Inc. announced that Christopher Posner, President and Chief Executive Officer, will present at the H.C. Wainwright 25th Annual Global Investment Conference on Monday, September 11, 2023, at 9:00 a.m. EDT in New York, NY.

uniQure N.V. announced that the U.S. Food and Drug Administration has cleared the Investigational New Drug application for AMT-260, the Company’s gene therapy candidate for refractory mesial temporal lobe epilepsy.

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, announced that Chandler D. Robinson, MD, Monopar’s Chief Executive Officer, will present at the H.C. Wainwright 25th Annual Global Investment Conference.

Axsome Therapeutics, Inc., a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system disorders, announced that Herriot Tabuteau, MD, Axsome’s Chief Executive Officer, will participate in three upcoming investor conferences in September.

Invivyd, Inc., a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, announced the appointment of William Duke as Chief Financial Officer.